|
|
|
|
SOLIMIDE TABLETS Back to Products
COMPOSITION Solimide: Each film coated, scored tablet contains 5mg Glibenclamide.
INDICATION Solimide is indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. Use of Solimide must be viewed by both the physician and the patient as a treatment in addition to diet and not as a substitution or a convenient mechanism for avoiding dietary restraint.
DOSAGE AND ADMINISTRATION Usual Starting Dose.
Transfer from other antidiabetic drugs. Transfer of patients from other oral antidiabetic drugs to Solimide should be done conservatively and the initial daily dose should be 2.5-5mg. When transferring patients from oral hypoglycemic drugs other than chlorpropamide to Solimide, no wash out period is required and no initial or priming dose are necessary. When transferring patients from chlorpropamide, particular care should be exercised during the first 2 weeks because the prolonged retention of chlorpropamide in the body and subsequent overlapping drug effects may provoke hypoglycemia.
Patients Receiving Insulin. Some Type II diabetic patients being treated with insulin may respond satisfactorily to Solimide. If insulin dose is less than 20 units daily, substitution of Solimide tablets 2.5-5mg as a single daily dose may be tried. If the insulin dose is between 20 and 40 units daily, the patient may be placed directly on Solimide 5mg daily as a single dose. If the insulin dose is more than 40 units daily, a transition period is required for before conversion to Solimide. In these patients, insulin dosage is decreased by 50% and Solimide 5mg daily is started.
Titration to Maintenance Dose The usual maintenance dose is 1.25-20mg daily, which may be given as a single dose or in divided doses. Dose increases should be made in increments of no more than 2.5mg at weekly intervals based upon the patient’s blood glucose response. Although no exact dose relationship exists between Solimide and other oral hypoglycemic drugs, patients may be transferred from the maximum dose of other sulfonylureas; the maximum starting dose of Solimide is 5mg daily. This should be observed as necessary before any dose adjustment. When transferring patients receiving more than 40 units of insulin daily, they should start Solimide on 5mg daily with a 50% reduction in their daily insulin. Progressive withdrawal of insulin and increase in dosage of Solimide should be in increment of 1.25-2.5mg every 2-10 days, during this conversion period when both Solimide and insulin are being used, hypoglycemia may rarely occur.
Concomitant Solimide and Metformin Therapy. Solimide should be added gradually to the dosing regimen of patients who have not responded to the maximum dose of metformin monotherapy after 4 weeks. With concomitant Solimide and metformin therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug.
Maximum Dose Daily doses of more than 20mg are not recommended.
Dosage Interval Once-a-day therapy is usually satisfactory. Some patients, particularly those receiving more than 10mg daily, may have a more satisfactory response with twice-a-day dosage.
SIDE EFFECTS Solimide is generally well tolerated, mild and infrequent side effects that are usually experienced includes gastrointestinal disturbance like nausea, vomiting, dyspepsia, diarrhea and constipation. Hypoglycemia may occur if the dosage is not optimized as explained above.
USE IN PREGNANCY Glibenclamide should only be used in pregnancy & lactation if the potential benefit outweighs the risk. However, it should be borne in mind that hypoglycemia may occur in nursing infants.
CONTRAINDICATIONS Glibenclamide is contraindicated in patients that are sensitivity to the drug and in diabetic ketoacidosis (with or without coma), insulin-dependent (juvenile) diabetes mellitus. Oral antidiabetic drugs should be avoided on the morning of surgery.
PRESENTATION Solimide Tablet 5mg packs of 30’s and 100’s.
For more information, please contact productmanager@solidumpharma.com Back to top |
Solimide
contains Glibenclamide, an oral blood-glucose lowering drug
of the class of sulfonylurea. It is used for the treatment of Type
II diabetes mellitus.
The usual starting
dose is 2.5-5mg daily administered with breakfast or the first meal
main meal. Those patients who may be more sensitive to hypoglycemic
drugs should be started at 1.25mg daily. Failure to follow
appropriate dosage regimen may precipitate hypoglycemia. Patients
who do not adhere to their prescribed dietary and drug regimen are
more prone to exhibit unsatisfactory response to therapy.